SecBot SecBot
6-K ·Filed Jun 15, 2026

RDY

DR REDDYS LABORATORIES LTD
BULLISH
Impact 6/10
Horizonweeks Processed5mo ago SEC0001575872-26-000418
Notable filing: 6-K
Actionable Insight ▲ Bullish

Traders should monitor Dr. Reddy's for potential revenue upside from the 180-day exclusivity period, but note that this is a single-strength launch in a competitive generic space. Watch for any subsequent first-to-file exclusivity on other strengths or additional generic oncology launches that could compound the impact.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$13.33
T+0 close · Jun 15, 2026 · via day close
Latest settled
−3.08%
T+20 · $12.92
Vs SPY
−2.33%
α at T+20
Next horizon
T+60
due 2mo ago
  1. T+0 · Jun 15 $13.33entry
  2. T+1 · 5mo ago −0.23%α +0.37% · $13.30
  3. T+5 · 5mo ago +4.35%α +5.73% · $13.91
  4. T+20 · 4mo ago −3.08%α −2.33% · $12.92
  5. T+60 · due 2mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's announced the first-to-market launch of Bosutinib Tablets 400mg (generic Bosulif) in the U.S., a tyrosine kinase inhibitor for oncology. The product was a first-to-file and qualifies for 180-day generic exclusivity for this strength. The Bosulif brand had U.S. sales of ~$253.8M over the latest 12 months ended April 2026. This is a positive, event-driven catalyst that expands Dr. Reddy's oncology portfolio, limited to a single strength and a finite exclusivity window.

Key Facts

  • First-to-market launch of Bosutinib Tablets 400mg, generic equivalent of Bosulif, in the United States on June 13, 2026.
  • Product is a first-to-file, eligible for 180-day generic exclusivity for this strength.
  • Brand Bosulif (400mg) had U.S. sales of approximately $253.8 million for the latest 12 months ended April 2026.
  • Dr. Reddy's holds exclusive marketing rights; MSN Laboratories is the development and manufacturing partner.
  • Launch expands Dr. Reddy's oncology portfolio in the U.S. market.

Financial Impact

U.S. brand sales of ~$253.8M (LTM) for the 400mg strength, but generic revenue will be a fraction of that and subject to competition after 180-day exclusivity.

revenuemarket share

Risk Factors

  • Generic pricing erosion and competition from other manufacturers after the 180-day exclusivity period
  • Product launch delays or supply disruptions from partner MSN Laboratories
  • Litigation risk from branded manufacturer (Wyeth/Pfizer) regarding patent validity or exclusivity scope

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000418
Document: 0001575872-26-000418-index.html0001575872-26-000418
Document: 0001575872-26-000418.txt0001575872-26-000418

Track record

73 reports on RDY

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 6 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026